Centene Corporation Share Price Target ‘$86.52’, now 33.3% Upside Potential

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Centene Corporation which can be found using ticker (CNC) have now 16 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $110.00 and $76.00 calculating the average target share price we see $86.52. (at the time of writing). Now with the previous closing price of $64.89 this indicates there is a potential upside of 33.3%. Also worth taking note is the 50 day moving average now sits at $70.05 and the 200 day moving average is $73.48. The market capitalization for the company is 34.66B. The stock price for the company is currently is currently $64.95 USD

The potential market cap would be $46,211,050,155 based on the market consensus.

The company has a dividend yield of 1.57%. Other points of data to note are a P/E ratio of 12.81, revenue per share of $264.74 and a 3.67% return on assets.

Centene Corporation is a healthcare company. The Company provides services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. It provides a range of managed healthcare products and services, primarily through Medicaid, Medicare, and commercial products. Its segments include Medicaid, Medicare, Commercial and Other. It offers Medicaid and Medicare members (including Medicare Prescription Drug Plans) as well as individuals and families served by the Health Insurance Marketplace and the TRICARE program. It also contracts with other healthcare and commercial organizations to provide a variety of specialty services focused on treating the whole person. Medicaid program provides health insurance to low-income families and individuals with disabilities. Medicare is a federal health insurance program for people ages 65 and over, which also covers people under 65 with certain disabilities and people with end-stage renal diseases.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

Search

Search